Rose-John, Stefan http://orcid.org/0000-0002-7519-3279
Jenkins, Brendan J. http://orcid.org/0000-0002-7552-4656
Garbers, Christoph
Moll, Jens M.
Scheller, Jürgen http://orcid.org/0000-0001-9932-1055
Article History
Accepted: 1 March 2023
First Online: 17 April 2023
Competing interests
: C.G. has received a research grant from Corvidia Therapeutics (Waltham, MA, USA) and has acted as a consultant/speaker for AbbVie and NovoNordisk. J.M.M. and J.S. declare that they have applied for a patent covering cs130Fc and c19s130Fc. J.M.M. has acted as a consultant for Ferring Pharmaceuticals. S.R.-J. has acted as a consultant and speaker for AbbVie, Chugai, Genentech Roche, Regeneron, Pfizer and Sanofi. He also declares that he is an inventor on patents owned by CONARIS Research Institute, which develops the sgp130Fc protein olamkicept together with Ferring Pharmaceuticals and I-Mab Biopharma. S.R.-J. has stock ownership in CONARIS. B.J.J. declares no competing interests.
Free to read: This content has been made available to all.